Gill A. Webster
4B Walls Rd
Penrose, AUK, New Zealand
Penrose, AUK, New Zealand
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Plasma IgG aggregates as biomarkers for multiple sclerosis.
Journal: Clinical immunology (Orlando, Fla.)
Published: June 09, 2023
Innate Signaling in the CNS Prevents Demyelination in a Focal EAE Model.
Journal: Frontiers in neuroscience
Published: March 18, 2021
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: November 24, 2020
Protective roles for myeloid cells in neuroinflammation.
Journal: Scandinavian journal of immunology
Published: May 01, 2020
Innate signaling within the central nervous system recruits protective neutrophils.
Journal: Acta neuropathologica communications
Published: October 29, 2019
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Journal: Cancer immunology, immunotherapy : CII
Published: March 22, 2019
Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
Journal: Journal for immunotherapy of cancer
Published: February 19, 2019
Toll-like receptor 9-dependent interferon production prevents group 2 innate lymphoid cell-driven airway hyperreactivity.
Journal: The Journal of allergy and clinical immunology
Published: September 05, 2018
MIS416 as a siRNA Delivery System with the Ability to Target Antigen-Presenting Cells.
Journal: Nucleic acid therapeutics
Published: June 13, 2018
MIS416 Enhances Therapeutic Functions of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Against Experimental Colitis by Modulating Systemic Immune Milieu.
Journal: Frontiers in immunology
Published: November 29, 2017
Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study.
Journal: Pilot and feasibility studies
Published: May 10, 2017
Last Updated: 09/26/2026